Merck provides update on development program for Suvorexant
Publication date: 6 February 2012
Author: Merck
Tagged with: Merck, Peter S. Kim
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for suvorexant, the company’s investigational orexin receptor antagonist, which, if approved, will be a new mechanism for the treatment of insomnia. The two pivotal Phase III efficacy trials for suvorexant have been completed and, based on the positive results of these studies, Merck plans to file a New Drug Application (NDA) for suvorexant with the U.S. Food and Drug Administration (FDA) in 2012.
Both Phase III studies were multicenter, randomized, double-blind, placebo-controlled clinical trials that evaluated suvorexant compared to placebo in adult patients ages 18 years and older. The primary endpoint was change from baseline in subjective total sleep time and time to sleep onset, wake time after persistent sleep onset, and latency to onset of persistent sleep at one and three months. Merck plans to submit these data for presentation at major medical meetings later this year.
Suvorexant is one of the five major U.S. filings Merck anticipates for 2012 and 2013.
“Suvorexant selectively targets an important pathway involved in helping to promote sleep and, if approved, will be a new, first-in-class treatment for patients with insomnia,” said Peter S. Kim, president, Merck Research Laboratories. “We are enthusiastic about the potential of this investigational medicine, and look forward to sharing the results from these studies with the medical community.”
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Novartis wins GBCHealth Business Action on Health Award for social ventures initiative (17 May 2013)
- Could a ‘super computer’ help improve epilepsy care? Yes, it’s elementary my dear WATSON (16 May 2013)
- Promising new data demonstrate that a novel pain therapy system manages patients with chronic neuropathic pain (16 May 2013)
- Roche’s obinutuzumab significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer (16 May 2013)
- AstraZeneca issues update on accelerated oncology pipeline in advance of 2013 ASCO Annual Meeting (16 May 2013)
Mass Spectrometry: In-depth focus
This free to view Mass Spectrometry in-depth focus features articles from experts at University of British Columbia and University of Colorado Denver.
Stem Cells: In-depth focus
This free to view Stem Cells in-depth focus features articles from experts at Max Planck Institute for Molecular Genetics, Heinrich Heine University and Newcastle University.
Company directory
ABB Analytical Measurements | Analytik Jena AG | Aptalis Pharmaceutical Technologies | ASM - Aerosl-Service AG | Azbil BioVigilant, Inc. | B&W Tek, Inc. | Bio-Optronics, Inc. | bioMérieux | BioTrends – Archilex SA | BMG LABTECH GmbH | Bruker Daltonik GmbH | CAMO Software AS | Catalent Pharma Solutions | Chemical Plant Equipment | Chemspec Europe Ltd | CI Precision | Dow Chemical Company Ltd | DSM Biologics | FOSS NIRSystems, Inc. | GE Analytical Instruments | GenScript USA Inc. | Gerresheimer Group | HACH LANGE GMBH | HAMAMATSU PHOTONICS EUROPE | I Holland Limited | IDBS | IONIMED Analytik GmbH | Lonza | MPI Research | Natoli Engineering Company, Inc. | PANalytical B.V. | Patheon Inc | ReAgent | Roche | Siemens AG | Sirius Analytical Instruments Ltd | TSI | Waters Corporation |
Login to access exclusive content